Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

Oragenics Q4 2023 Earnings Report

Oragenics logo
$0.29 +0.00 (+1.03%)
As of 02/21/2025 04:00 PM Eastern
Earnings History

Oragenics EPS Results

Actual EPS
-$5.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Q4 2023
Date
3/29/2024
Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com
February 17, 2025 | americanbankingnews.com
Oragenics announces partnership with BRAINBox Solutions
February 11, 2025 | markets.businessinsider.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
February 11, 2025 | globenewswire.com
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
February 5, 2025 | globenewswire.com
Oragenics appoints Huffman as interim CEO, provides shareholder update
January 23, 2025 | markets.businessinsider.com
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSE:OGEN), a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

View Oragenics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles